Donor contributions and commitments

National governments and institutions support GAVI in three different ways by:

direct donations to GAVI
making long-term pledges to The International Finance Facility for Immunisation (IFFIm) which in turn gives GAVI large one-off grants
making pledges to The Advance Market Commitment (AMC) which is supporting the development and availability of a pneumococcal vaccine for developing countries.

Learn more about each donor’s support below.

Core funding (2006-2009): US$ 20 million: Australia’s grant agreement with the GAVI Alliance covers 2006-2009, with a US$ 5 million contribution per year. To-date, Australia has contributed US$ 20 million to the Alliance.
HSS extension of IFFIm: 250 million Australian dollars over 20 years: In September 2009, Australia announced a commitment to the IFFIm of 250 million Australian dollars over 20 years for health systems strengthening.
Core funding (2002-2006): US$ 149 million: Canada made its first contribution in 2002, with a donation of US$ 2 million. Canada’s most recent grant agreement with the GAVI Alliance covers 2006-2008. To-date, Canada has contributed US$ 149 million to the Alliance.
AMC: US$ 200 million: In February 2007, Canada committed US$ 200 million to launch the first Advance Market Commitment (AMC) to help speed the development and availability of pneumococcal vaccines.
Core funding (2001-2009): US$ 26 million: Denmark is one of the GAVI Alliance’s original six donor countries. Denmark made a first contribution of US$ 1 million in 2001. Denmark’s latest grant agreement amounts to 125 million Danish kroner (US$ 24 million**) over 5 years (2007-2011). To-date, Denmark has contributed US$ 26 million to the Alliance.
Core funding (2003-2009): US$ 58 million: Since 2003, the European Commission has committed a total of up to €43 million (US$ 58 million**). €23 million of this comes from the Development Co-operation Instrument (DCI), and €20 million comes from the intra-ACP envelope in the ninth European Development Fund for the benefit of ACP countries. To-date, the European Commission has contributed a total of US$ 58 million to the Alliance.
Core funding (2004-2006): €15 million (US$ 19 million**): For the period 2004 to 2006, France made an annual contribution of €5 million. To-date, France has contributed a total of €15 million to the GAVI Alliance.
IFFIm: €1.24 billion to IFFIm over 20 years (US $ 1.74 billion*): In 2006, France made an initial commitment to IFFIm of €373 million over 20 years. An additional pledge in 2007 for 19 years brings France’s total commitment to IFFIm to €1.24 billion.
Core funding (2006-2009): €12 million (US$ 17 million**): Germany made a first donation of €4 million (US$ 5 million**) to the GAVI Alliance in 2006. The most recent donation of Germany amounts to €4 million in 2009. To-date, Germany has contributed a total of €12 million to the Alliance.
Core funding (2002-2009): €19 million (US$ 26 million**): Ireland made a first contribution of US$ 0.5 million to the GAVI Alliance in 2002. The most recent grant agreement amounts to €18 million (US$ 24 million*) over three years (2006-2008). In 2009, Ireland made a total contribution of €2.5 million (US$ 3.5 million**), bringing Ireland’s total financial support to the Alliance since 2002 to US$ 26 million.
IFFIm: €473.5 million over 20 years (US$ 600 million*): In 2006, the Italian Government committed €473.5 million to IFFIm over 20 years.
AMC: US$ 635 million: In February 2007, Italy committed US$ 635 million to launch the first Advance Market Commitment (AMC) to help speed the development and availability of pneumococcal vaccines.
Core funding (2005-2009): US$5.4 million: Luxembourg made a first contribution of US$ 0.6 million in 2005 to the GAVI Alliance. In 2008, Luxembourg increased its annual support to US$1.4 million. To-date, Luxembourg has contributed US$ 5.4 million to the Alliance.
Core funding (2001-2009): US$ 191 million: The Netherlands is one of the GAVI Alliance’s original six donor countries. The Netherlands made a first contribution of US$ 25 million in 2001. The country’s most recent grant agreement amounts to US$ 36 million per year over four years (2007-2010). To-date, the Netherlands has contributed US$ 191 million to the Alliance.
IFFIm: €80 million (US$ 100 million*) over seven years (2009-2016): The Netherlands joined the IFFIm donor group in 2009 committing €80 million (US$ 100 million*) over seven years.
Core funding (2001-2009): US$ 441 million: Norway is one of the GAVI Alliance’s original six donor countries. Norway made a first contribution of US$ 18 million in 2001. Norway’s contribution in 2009 amounts to US$ 82.8 million. To-date, Norway has contributed US$ 441 million to the Alliance.
IFFIm: US$ 27 million over 5 years: Norway committed US$ 27 million to IFFIm over five years in 2006.
HSS extension of IFFIm: 1.5 billion Norwegian kroner over 10 years: In September 2009, Norway announced an extension to the IFFIm of 1.5 billion Norwegian kroner for health systems strengthening over 10 years.
AMC: US$ 57 million: In February 2007, Norway committed up to US$ 57 million to launch the first Advance Market Commitment (AMC) to help speed the development and availability of pneumococcal vaccines.
AMC: US$ 80 million: In February 2007, the Russian Federation committed US$ 80 million to launch the first Advance Market Commitment (AMC) to help speed the development and availability of pneumococcal vaccines.
IFFIm: US $ 20 million over 20 years: South Africa joined the IFFIm donor group in 2007 committing US$ 20 million over 20 years.
Core funding (2008-2009): €29 million (US$ 40.5 million**): The Spanish government made its first contribution to the GAVI Alliance in 2008, with €29 million over 2 years.
IFFIm: €189.5 million over 20 years (US$ 240 million*): Spain became a donor to IFFIm in 2006 with a commitment of €189.5 million over 20 years.
Core funding (2001-2009): US$ 86 million: Sweden is one of the GAVI Alliance’s original six donor countries. Sweden made a first contribution of US$ 2 million to the Alliance in 2001. Sweden’s current grant agreement amounts to 150 million Swedish kroner (approximately US$ 22 million) for two years (2009-2010). To-date Sweden has contributed a total of US$ 86 million to the Alliance.
IFFIm: 276 million Swedish kroner (US$ 38 million*) over 15 years: Sweden also committed funds to IFFIm in 2007 with a total of 276 million Swedish kroner to be paid over 15 years.
Core funding (2000-2007): US$ 122 million: The United Kingdom is one of the GAVI Alliance’s original six donor countries. In 1999, the UK made a first contribution of US$ 4.5 million. The UK’s latest grant agreement covers 2006-2008. To-date, the UK has contributed US$ 122 million to the Alliance.
IFFIm: £ 1.38 billion (US$ 2.58 billion*) over 20 years: In 2006 the UK committed a total of £ 1.38 billion to IFFIm over 20 years.
HSS extension of IFFIm: £ 250 million: In September 2009, the United Kingdom announced an extension to the IFFIm of £ 250 million for health systems strengthening over 10 years.
AMC: US$ 485 million: In February 2007, the UK committed US$ 485 million to launch the first Advance Market Commitment (AMC) to help speed the development and availability of pneumococcal vaccines.
Core funding (2001-2009): US$ 569 million: The United States of America is one of the GAVI Alliance’s original six donor countries. The USA made a first contribution of US$ 48 million in 2001. In 2009, the USA contributions amounted to US$ 75 million. To-date, the USA has contributed a total of US$ 569 million over nine years.
Core funding (1999-2009): US$ 1.14 billion: The Bill & Melinda Gates Foundation is a founding partner of the GAVI Alliance. Its initial five-year grant in 1999 helped establish the GAVI Fund. The Foundation pledged a further US$ 750 million in 2005 to support the Alliance’s work, committing a total of US$ 1.51 billion to the end of 2014.
AMC: US$ 50 million: In February 2007, the Bill & Melinda Gates Foundation committed US$ 50 million to launch the first Advance Market Commitment (AMC) to help speed the development and availability of pneumococcal vaccines.
Core funding (2000-2009): US$ 11 million: Philanthropists, foundations and individual donors contribute to the GAVI Alliance.
Core funding (2008-2009): US$ 12 million: Since 2008, La Caixa Foundation has contributed a total of US$ 12 million to the GAVI Alliance.

* converted as of date of commitment
** converted as of date of contribution

Related downloads

Cash received by GAVI 1999-2009 (PDF - 95KB)

Donor contributions and commitments

See also

Related downloads